For research use only
| Cat No. | ABC-TC0266 |
| Product Type | Human Kidney Cancer Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Rhabdoid Tumor |
| Product Code | G401; G 401 |
Wilms' tumor (embryonal carcinosarcoma of kidney)
G-401 is a human malignant rhabdoid tumor (MRT) cell line isolated from the kidney of a White, 3-month-old male infant. This G401 cell line exhibits epithelial-like morphology and grows as an adherent monolayer culture. Cytogenetic and molecular analyses reveal the hallmark genetic alteration of MRTs: inactivation of the *SMARCB1/INI1* tumor suppressor gene on chromosome 22. The cells also exhibit chromosomal heterogeneity, including clones with derivative chromosome 12 arising from partial trisomy of 7p, rather than a stable diploid karyotype. G-401 cells express nephroblast growth factor (NB-GF). They are tumorigenic. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | G401; G 401 |
| Species | Human |
| Cat.No | ABC-TC0266 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Rhabdoid Tumor |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Kidney Cancer Cell Lines |
G-401 cells serve as a critical in vitro model for studying the molecular pathogenesis of malignant rhabdoid tumors (MRTs). Its primary applications include cancer biology research to elucidate tumorigenic mechanisms and drug screening for evaluating potential therapeutics targeting MRTs. For example, it enables pharmacogenomic profiling to identify compounds effective against rhabdoid tumor proliferation pathways. This cell line is further utilized in tumorigenicity assays to validate oncogenic phenotypes and therapy responses.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
